Who Owns Outlook Therapeutics Stock?
NASDAQ: OTLKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 16.67%
- Held by insiders
- 12.64%
- Institutional holders
- 82
- Institutions 16.7%
- Insiders 12.6%
- Public and other 70.7%
Who owns Outlook Therapeutics stock?
Institutional investors own about 16.7% of Outlook Therapeutics's shares, spread across 82 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 12.64% of OTLK.
The largest institutional holders are Vanguard Capital Management LLC (1.80%), Perceptive Advisors Llc (1.29%) and Marshall Wace LLP (0.82%). Together, the top 10 institutions control 6.9% of shares outstanding. In their latest filings, 9 of the top 10 institutions increased their OTLK positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of OTLK
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Vanguard Capital Management LLC | 4.38M | 1.80% | +122.5% |
| Perceptive Advisors Llc | 3.14M | 1.29% | +100.0% |
| Marshall Wace LLP | 1.99M | 0.82% | +100.0% |
| Blackrock Inc. | 1.67M | 0.69% | +249.5% |
| Jane Street Group, LLC | 1.43M | 0.59% | +100.0% |
| Geode Capital Management, LLC | 1.25M | 0.51% | +106.4% |
| Susquehanna International Group, LLP | 968.19K | 0.40% | +622.1% |
| HRT Financial LP | 784.90K | 0.32% | +1058.4% |
| Vanguard Fiduciary Trust Co | 661.66K | 0.27% | +274.8% |
| Gilpin Wealth Management, LLC | 555.00K | 0.23% | -7.5% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of OTLK
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.07M | 1.26% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.23M | 0.51% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 529.17K | 0.22% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 197.06K | 0.08% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 159.58K | 0.07% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 89.38K | 0.04% |
| VANGUARD Inst. INDEX Fd.S-Vanguard Inst. Total Stock Market Index Fd. | 46.11K | 0.02% |
| VANGUARD VALLEY FORGE FUNDS-Vanguard Balanced Index Fund | 29.62K | 0.01% |
| ADVISORS' INNER CIRCLE III-Knights of Columbus U.S. All Cap Index Fund | 603 | 0.00% |
Frequently asked questions
Who is the largest shareholder of Outlook Therapeutics?
Vanguard Capital Management LLC is the largest institutional shareholder of OTLK, owning 1.80% of shares outstanding (4.38M shares) as of its latest 13F filing.
What percentage of Outlook Therapeutics is owned by institutions?
Institutions own about 16.7% of OTLK shares and 19.1% of the public float.
How much of Outlook Therapeutics do insiders own?
Insiders, such as officers and directors, own about 12.64% of OTLK shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.